The implications of the ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression trial: A return to first principles

Clinical Cardiology

Volumn 31, Issue 6, 2008, Pages 288-290

  Musunuru, Kiran ^a,b   Blumenthal, Roger S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

ENHANCE trial; Ezetimibe; Hypercholesterolemia

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; CERIVASTATIN; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; RESIN; ROSUVASTATIN; SIMVASTATIN;

ABSENCE OF SIDE EFFECTS; ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; CAROTID ARTERY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED DRUG RELEASE; DRUG EFFICACY; DRUG SAFETY; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; HYPERCHOLESTEROLEMIA; IMAGING; MONOTHERAPY; REMISSION; REVIEW; RHABDOMYOLYSIS; TREATMENT OUTCOME;

ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; AZETIDINES; CHOLESTEROL; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; SIMVASTATIN; TREATMENT OUTCOME;

EID: 46949084239     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.20405     Document Type: Review

References (10)

1. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, et al.: Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008;358:1431-1443
2. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, et al.: Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001;357:577-581
3. Crouse JR III, Raichlen JS, Riley WA, Evans GW, Palmer MK, el al.: Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 2007;297:1344-1353
4. Underhill HR, Yuan C, Zhao XQ, Kraiss LW, Parker DL, et al.: Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial. Am Heart J 2008;155:584.e1-584.e8
5. Ridker PM, JUPITER Study Group: Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation 2003;108:2292-2297
6. Clinical Trial. IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin. Available from http://www.clinicaltrials.gov/show/NCT00202878 [Accessed 7 April 2008]
7. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, et al.: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-1592
8. Clinical Trial. AIM HIGH: Niacin Plus Statin to Prevent Vascular Events. Available from http://www.clinicaltrials.gov/show/NCT00120289 [Accessed 7 April 2008]
9. Keech A, Simes RJ, Barter P, Best J, Scott R, et al.: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-1861
10. Clinical Trial. ACCORD: Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. Available from littp://www.clinicaltrials.gov/show/NCT00000620 [Accessed 7 April 2008]